SEC Filing Analysis: Jasper Therapeutics, Inc. (JSPR)

Executive Summary

• Trading Significance: High
• Key Takeaway: Institutional investor Qiming U.S. Healthcare Fund II, L.P. reported its ownership stake in Jasper Therapeutics fell to 3.3%, dropping below the 5% reporting threshold. This was primarily caused by a massive ~72% increase in the company's total shares outstanding, representing a significant dilution event.
• Market Impact: The disclosure of substantial share dilution is a material negative event for existing shareholders, as it reduces ownership concentration and can place downward pressure on the stock price.

Company Information

Field	Value
Company	Jasper Therapeutics, Inc.
Ticker Symbol	JSPR
CIK	0001788028
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Qiming U.S. Healthcare Fund II, L.P.
CIK	0001765710
Title/Position	N/A
Relationship	10% Owner (Passive Investor)

Transaction Details

Field	Value
Form Type	SCHEDULE 13G/A
Event Date	2025-09-30
Transaction Code	N/A
Security Type	Voting Common Stock
Shares Involved	Not specified
Price Per Share	Not specified
Total Value	Not specified
Shares Owned After	928,964
Ownership Type	Direct (by the fund)

Financial Impact Assessment

Dilution Materiality

This filing does not report a specific transaction but rather a change in the percentage of ownership. The most significant information is the change in the company's share structure.

Metric	Value
Shares Outstanding (per Market Data)	16,253,332
Shares Outstanding (per Filing, as of 09/30/25)	27,984,039
Increase in Shares	11,730,707
% Increase in Shares (Dilution)	72.17%
Filer's Post-Dilution Ownership	928,964 shares (3.3% of outstanding)
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: For a nano-cap company with a market capitalization of $50 million, a ~72% increase in shares outstanding is an extremely material event. It fundamentally alters the per-share value and ownership structure.
• Ownership Concentration: Qiming's stake was diluted from a potential 5.7% (based on the previous share count of 16.25M) to 3.3%. This demonstrates how significantly the new share issuance has impacted major holders and, by extension, all other shareholders.
• Transaction Significance: The significance lies not in a sale by the insider, but in the issuer's actions (e.g., a large equity financing round, shares issued for an acquisition) that led to the dilution. The filing is the vehicle that brings this dilution to light.

Market Impact Analysis

Stock Impact Prediction

• Direction: Negative
• Reasoning: A ~72% dilution significantly reduces each existing share's claim on the company's earnings and assets. This is typically viewed negatively by the market as it can lead to a re-pricing of the stock to reflect the larger number of shares.

Volume & Sentiment

• Expected Volume Impact: Potential for increased trading volume as the market digests the news of the substantial dilution.
• Sentiment Indicator: Bearish

Investment Insights

Positive Market Indicators

• None are evident from this filing. The filing indicates a passive investment stance, and the primary event is dilution.

Risk Factors

• Massive Share Dilution: The primary risk highlighted is the ~72% increase in shares outstanding, which severely dilutes existing shareholders.
• Capital Needs: Such a large share issuance suggests the company has significant capital requirements, which may be for funding operations, R&D, or acquisitions. Investors should investigate the reason for the capital raise.

Key Takeaways

1. Major Dilution Event: Jasper Therapeutics' outstanding shares increased by approximately 72%, a highly material event for investors.
2. Passive Holder Stake Reduced: As a result of the dilution, institutional investor Qiming's stake fell from above 5% to 3.3%, triggering this amended filing.
3. Focus on Issuer's Actions: The key story is not the investor's action but the company's, which has fundamentally altered its equity structure.

Additional Context

Transaction Notes

• This Schedule 13G/A filing indicates a change in beneficial ownership for a passive investor. The filer certifies they do not hold the securities for the purpose of changing or influencing control of the company.
• The event triggering the filing is the ownership level as of September 30, 2025.